Syndax Pharmaceuticals (NASDAQ:SNDX) Trading 3.6% Higher - What's Next?

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) shot up 3.6% on Monday . The company traded as high as $11.56 and last traded at $11.95. 33,962 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 1,577,569 shares. The stock had previously closed at $11.54.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on SNDX. HC Wainwright restated a "buy" rating and set a $51.00 target price on shares of Syndax Pharmaceuticals in a report on Tuesday, March 4th. Scotiabank dropped their target price on Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating for the company in a report on Wednesday, January 8th. StockNews.com upgraded Syndax Pharmaceuticals to a "sell" rating in a report on Thursday, April 10th. JPMorgan Chase & Co. upped their price objective on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a report on Thursday, March 20th. Finally, Citigroup reduced their target price on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $36.20.

Syndax Pharmaceuticals Stock Up 0.2 %

The business has a 50-day simple moving average of $13.08 and a 200-day simple moving average of $14.89. The company has a market cap of $1.15 billion, a PE ratio of -3.67 and a beta of 1.28.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The company had revenue of $7.68 million during the quarter, compared to analysts' expectations of $86.32 million. As a group, equities research analysts predict that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current fiscal year.

Insider Transactions at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, CFO Keith A. Goldan sold 3,777 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $58,543.50. Following the sale, the chief financial officer now directly owns 90,746 shares in the company, valued at $1,406,563. This represents a 4.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael A. Metzger sold 13,288 shares of the business's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $205,964.00. Following the completion of the transaction, the chief executive officer now owns 300,121 shares of the company's stock, valued at approximately $4,651,875.50. This trade represents a 4.24 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 21,683 shares of company stock valued at $336,087. 4.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. R Squared Ltd acquired a new position in shares of Syndax Pharmaceuticals during the fourth quarter worth about $26,000. Virtus ETF Advisers LLC grew its holdings in Syndax Pharmaceuticals by 18.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock worth $70,000 after acquiring an additional 827 shares in the last quarter. Cape Investment Advisory Inc. grew its holdings in Syndax Pharmaceuticals by 157.1% during the 4th quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company's stock worth $85,000 after acquiring an additional 3,927 shares in the last quarter. KBC Group NV increased its position in shares of Syndax Pharmaceuticals by 104.8% in the 4th quarter. KBC Group NV now owns 6,954 shares of the company's stock valued at $92,000 after purchasing an additional 3,559 shares during the last quarter. Finally, Optimize Financial Inc acquired a new stake in shares of Syndax Pharmaceuticals in the 4th quarter valued at $152,000.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).